Figure 2.
eIF4E+/- and eIF4Efl/+ p190 have a growth disadvantage
(A) Experimental scheme of competitive outgrowth assay of WT or eIF4E+/- p190 BCR-ABL.
(B) Growth of p190 cells was monitored in vitro over 9 days. Percentage of hCD4 and GFP marker positive cells were measured with flow cytometry. Data are expressed as mean ± SEM. (∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 two-way ANOVA, n = 3 per genotype).
(C) Log of ratio of hCD4+/GFP+ was measured by flow cytometry. Data are expressed as mean ± SEM. (∗p < 0.05, ∗∗p < 0.01, one way ANOVA, n = 9 or 10 mice/group). Representative flow cytometry plots of bone marrow analyzed for frequency of WT and Het leukemia cells before and after injection of an equal ratio of hCD4 WT and GFP Het p190.
(D) Experimental scheme of maintenance assay of WT or eIF4E fl/+ p190 BCR-ABL with 100% marker positivity.
(E) Competitive growth assay of established hCD4 and GFP p190 eIF4E+/+ Cre+ and eIF4E fl/+ Cre+ treated with 1 μM 4OHT. Percentage of hCD4 and GFP marker positive cells were measured by flow cytometry. Data are expressed as mean ± SEM. (∗∗∗∗p < 0.0001 two-way ANOVA, n = 6–10/each combination).